Incepta Pharmaceuticals Ltd. is now recognized as the fastest growing of the top five pharmaceuticals dosage form manufacturing company in the country. Established in the year 1999, the company has come a long way. A completely new production facility dedicated to the production of cephalosporins including injectable product is now in operation. The company now produces all types of solid, liquid and semisolid dosage forms.

Incepta now has one of the largest and comepetent sales force and large distribution network of its own, operated from 13 different locations throughout the country. A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. These highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its products.

1999
February 1999, the construction of the factory began.
August 1999, office operations began.
December 1999, first batch of product (Ranitidine) was produced.

2000
January 2000, sales began formally.
February 2000, training of the first batch of medical representatives began.
April 2000, with the launching of Osartil the first prescription products of Incepta came to the market. The company started off in a new direction. Celenta, Rofenta and Omidon followed on the footsteps of Osartil.
A total of 23 new generics with 35 presentations were launched this year. Four of these generics were first ever in Bangladesh.
By the end of 2000 Incepta was the number 31 st company of the country.

2002
A total of 32 new generics with 49 presentations were launched. 14 of these generics were first ever in Bangladesh.
Massive expansion project of the factory was envisioned. New office for the sales and distribution operation was also taking shape. The company registered an excellent growth of 55.85% over the previous year.
By the end of the year Incepta was ranked the 10 th company of the country.

2003
A total of 32 new generics with 48 presentations were launched. 18 of these generics were first ever in Bangladesh. The new office for the sales and distribution operation was inaugurated.
The company registered an excellent growth of 28.5% over the previous year.
By the end of the year Incepta was ranked the 8 th company of the country.

2004
A total of 17 new generics with 32 presentations have been launched. 6 of these generics were first ever in Bangladesh (up to June 2004).
The company is maintaining an excellent growth of 48.2% over the previous year (up to June 2004).
The ranking are up again and the company is currently ranked the 5 th largest company of the country with the highest growth rate among the top five.